EcoDrugPlus

Cytochrome P450 26a1

Ensembl ID : ENSELUG00000017140
Gene Symbol: LOC105025284
3 Cross references
195 Possible Orthologues:

Cytochrome P450 3a27

Ensembl ID : ENSELUG00000010319
Gene Symbol: LOC105009627
3 Cross references
574 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSELUG00000010202
Gene Symbol: LOC105009626
3 Cross references
574 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSELUG00000020564
Gene Symbol: CYP19A1
4 Cross references
246 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSELUG00000003585
Gene Symbol: CYP19A1A
1 Cross references
255 Possible Orthologues:

Cytochrome P450, Family 46, Subfamily A, Polypeptide 1, Tandem Duplicate 3

Ensembl ID : ENSELUG00000018130
Gene Symbol: CYP46A1.3
1 Cross references
259 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSELUG00000008712
Gene Symbol: LOC105007147
3 Cross references
200 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSELUG00000005370
Gene Symbol: LOC105018848
3 Cross references
188 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSELUG00000022309
Gene Symbol: DGAT1
3 Cross references
192 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSELUG00000018016
Gene Symbol: DHODH
3 Cross references
173 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1

Ensembl ID : ENSELUG00000009395
Gene Symbol: LOC105013561
3 Cross references
198 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1

Ensembl ID : ENSELUG00000001596
Gene Symbol: LOC105016828
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).